COMPARISON OF NAPI2B EXPRESSION FROM PAIRED TISSUE SAMPLES IN A CLINICAL STUDY OF UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) SUPPORTS A STRATEGY OF TESTING IN ARCHIVE MATERIAL

被引：0

作者：

Richardson, Debra ^{[1
]}

Barve, Minal ^{[2
]}

Saltos, Andreas ^{[3
]}

Papadopoulos, Kyriakos ^{[4
]}

Hays, John ^{[5
]}

Tolcher, Anthony ^{[6
]}

Ellard, Susan ^{[7
]}

Doroshow, Deborah ^{[8
]}

Mitchell, Paul ^{[9
]}

Zarwan, Corrine ^{[10
]}

Werner, Theresa ^{[11
]}

Anderson, Charles ^{[12
]}

Spira, Alex ^{[13
]}

Mileshkin, Linda ^{[14
]}

Bradshaw, Chelsea ^{[15
]}

Demars, Leslie ^{[16
]}

Mosher, Rebecca ^{[17
]}

Hamilton, Erika ^{[18
]}

机构：

[1] Univ Oklahoma, Stephenson Canc Ctr, Gynecol Oncol, Oklahoma City, OK USA

[2] Texas Oncol, Mary Crowley Canc Res, Dallas, TX USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[4] START San Antonio, Med Oncol, San Antonio, TX USA

[5] Ohio State Univ, James Canc Ctr, Med Oncol, Columbus, OH 43210 USA

[6] NEXT Texas Oncol, Med Oncol, San Antonio, TX USA

[7] Univ British Columbia, Bc Canc Agcy, Vancouver, BC, Canada

[8] Mt Sinai, Med Oncol, New York, NY USA

[9] Austin Hlth, Olivia Newton John Canc Ctr, Med Oncol, Heidelberg, Australia

[10] Lahey Hosp, Med Oncol, Burlington, MA USA

[11] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA

[12] Willamette Valley Canc Inst & Res Ctr, Med Oncol, Eugene, OR USA

[13] Virginia Canc Specialists, Med Oncol, Fairfax, VA USA

[14] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[15] Mersana Therapeut, Dev Management, Cambridge, MA USA

[16] Mersana Therapeut, Clin Dev, Cambridge, MA USA

[17] Mersana Therapeut, Translat Med, Cambridge, MA USA

[18] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP017/#425

引用

页码：A55 / A56

页数：2

共 7 条

[1] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[2] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[3] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Lakhani, Nehal
Burns, Timothy
Barve, Minal
Edenfield, Jeffery
Hays, John
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Buscema, Joseph
Bernardo, Patricia
Keeton, Erika
Carrington, Cassandra
Burger, Robert
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
[4] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Hamilton, E. P.
Barve, M. A.
Tolcher, A. W.
Buscema, J.
Papadopoulos, K. P.
Zarwan, C.
Anderson, C. K.
Doroshow, D.
Wang, D.
Huebner, D.
Jansen, V. M.
Jarlenski, D.
Mosher, R.
Kaufman, J.
Moore, K. N.
Richardson, D. L.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
[5] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[6] Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A post-hoc analysis of a phase 1b expansion study in ovarian cancer
Monk, Bradley
Concin, Nicole
Richardson, Debra
Ray-Coquard, Isabelle
Pothuri, Bhavana
Marth, Christian
Bernardo, Patricia
Burger, Robert
Im, Ellie
Aldairy, Wassim
Coleman, Robert
Mirza, Mansoor
[J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S166
[7] Archival vs fresh tumor samples for assessing the gene expression of NaPi2b and immune-related genes in the Phase 1b study of Upifitamab Rilsodotin (UpRi) in platinum-resistant ovarian cancer
Lu, M.
Shaw, P.
Richardson, D.
Hamilton, E.
Bernardo, P.
Bradshaw, C.
Tolcher, A.
Mosher, R.
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : S88 - S89

← 1 →